106P Sentinel lymph node after neoadjuvant chemotherapy in patients with locally advanced breast cancer

Abstract

Background Sentinel lymph node provides reliable node staging information for clinically node negative and chemo naive breast cancer patients while its role after neoadjuvant chemotherapy remains unclear due to high false negative rate reported in previous studies. Methods From may 2015 to may 2016 33 patients were enrolled all ofthem received neoadjuvant chemotherapyfor locally advanced breast cancer patients underwent sentinel lymph node using blue dye and axillary lymph node dissection. Results 33 patients underwent sentinel lymph node and axillary lymph node dissection following neoadjuvant chemotherapy no cancer was found in the axillary lymph nodes of8 patientsPCR24,3%in5 patientscancerwasnotidentifiedin thesentinellymph node but was found in lymph nodes obtained from axillary lymph node dissection (false negative rate 15,2%). Conclusions Among women receiving neoadjuvant chemotherapy the false negative rate was not 10% or less so we can't support the sentinel lymph node as alternative to axillary lymph node dissection another change in approach and patients selection may improve sentinel lymph node sensitivity . Legal entity responsible for the study Obstetrics Gynecology University Hospital Funding Obstetrics Gynecology University Hospital Disclosure All authors have declared no conflicts of interest.